Results 41 to 50 of about 142 (121)
Mycoses, Volume 69, Issue 2, February 2026.ABSTRACT Background Invasive candidiasis (IC), life‐threatening fungal infections with high economic burden, are often treated first‐line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non‐inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in ...
Noemi Muszbek +10 more
wiley +1 more source
New Perspectives on Antimicrobial Agents: Rezafungin
Antimicrobial Agents and ChemotherapyABSTRACT Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins.
Nicholas M. Forrister +2 more
openaire +2 more sources
EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Rezafungin is a new long-acting echinocandin currently in phase 3 development. Epidemiological cutoff values are necessary for breakpoint setting but have not been established due to unexplained interlaboratory MIC variations observed in a prior multicenter study.
Maiken Cavling Arendrup +4 more
openaire +3 more sources
Mycoses, Volume 69, Issue 2, February 2026.ABSTRACT Background Echinocandins are the first‐line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once‐weekly intravenous administration, offering potential advantages in complex clinical settings.
Jorge Boán +10 more
wiley +1 more source
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician
Infection and Drug Resistance, 2023 Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj
Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field
Journal of Fungi, 2022 Acute lymphoblastic leukemia (ALL) patients comprise a highly immunocompromised group due to factors associated either with the treatment or the disease itself.
Christos Stafylidis +4 more
doaj +1 more source
Case Reports in Pulmonology, Volume 2026, Issue 1, 2026.Aspergillus niger and Aspergillus calidoustus are relatively uncommon pathogens that could cause invasive disease, especially in immunocompromised patients. We present the case of a 61‐year‐old male with a history of idiopathic pulmonary fibrosis who was admitted to our hospital for a unilateral lung transplant that was performed without complications;
Carlos Enrique Calvache Benavides +5 more
wiley +1 more source
Mycoses, Volume 68, Issue 12, December 2025.ABSTRACT Invasive candidiasis is a life‐threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifungal treatment are essential to improving patient outcomes and limiting unnecessary use of healthcare resources.
O. A. Cornely +7 more
wiley +1 more source
PharmaceuticsBackground/Objectives: Certain yeast species are recognized as significant opportunistic pathogens, capable of causing severe systemic infections, particularly in immunocompromised individuals or those with disrupted physiological barriers.
Iwona Skiba-Kurek +6 more
doaj +1 more source
Journal of Clinical Laboratory Analysis, Volume 39, Issue 21, November 2025.Antimicrobial resistance in Candida spp. is significant in individuals with HIV/AIDS infections, particularly in Iran. In this systematic review, a comprehensive systematic search was conducted to identify all the eligible studies between 1999 and 2024; the pooled resistance rates of Candida spp. against antimicrobial agents were estimated. The risk of
Aliasghar Fakhri‐Demeshghieh +8 more
wiley +1 more source